Assessment of response to therapy using conventional imaging

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 30, Issue SUPPL. 1, 2003, Pages

  Rankin, Sheila C ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

CT; Lymphoma; MRI; Residual masses; Therapeutic response

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

BONE MARROW METASTASIS; CANCER GROWTH; CANCER RECURRENCE; CANCER REGRESSION; CANCER THERAPY; COMPUTER ASSISTED TOMOGRAPHY; FOLLOW UP; HODGKIN DISEASE; HUMAN; IMAGING; LYMPHOMA; MINIMAL RESIDUAL DISEASE; NONHODGKIN LYMPHOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; REVIEW;

EID: 0038128305     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-003-1162-9     Document Type: Review

References (49)

1. Miller A, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981; 47:207.
2. Dixon DO, McLaughlin P, Hagemeister FB, et al. Reporting outcomes in Hodgkin's disease and lymphoma. J Clin Oncol 1987; 5:2773-2778.
3. Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989; 7:1630-1636.
4. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999; 17:1244-1253.
5. Grillo-Lopez AJ, Cheson B, Horning S. Response criteria (RC) for NHL: importance of "normal" lymph node (LN) size and correlations with response. Blood 1998; 92:41 2a (abs 1701). Suppl 1.
6. Mack MG, Balzer JO, Straub R, Eichler K, Vogl TJ. Superparamagnetic iron oxide-enhanced MR imaging of head and neck lymph nodes. Radiology 2002; 1:239-244.
7. Bussar Maatz R, Weissbach L. Retroperitoneal lymph node staging in testicular tumours. TNM study group. Br J Urol 1993; 72:234-240.
8. Tio TL, Kallimaris GE. Endosonographic ultrasounograpby of perigastric intestinal lymph nodes. Endoscopy 1994; 26:776-779.
9. Sakaguchi T, Yamashita Y, Katahira K, et al. Differential diagnosis of small round cervical lymph nodes: comparison of power Doppler US with contrast-enhanced CT and pathologic results. Radiat Med 2001; 19:119-125.
10. Surbone A, Lango DL, deVitra VT, et al. Residual abdominal masses in aggressive non-Hodgkin's lymphoma after combination chemotherapy: significance and management. J Clin Oncol 1988; 6:1832-1837.
11. Lewis E, Bernardino ME, Salvador PG, Cabanillas FF, Barnes PA, Thomas JL. Post therapy CT detected mass in lymphoma patients: is it viable tissue? J Comput Assist Tomogr 1982; 6:792-795.
12. Husband JE. Diagnostic techniques: their strength and weaknesses. Br J Cancer 1980 (Suppl 1 V) 41:21.
13. Hopper KD, Kasales CJ, van Slyke MA, Schwartz TA, Tenhave TR, Jozefiak JA. Analysis of interobserver and intra-observer variability in CT tumor measurements. AJR Am J Roentgenol 1996; 167:851-854.
14. Apter S, Avigdor A, Gayer G, Portnoy O, Zissin R, Hertz M. Calcification in lymphoma occurring before therapy: CT features and clinical correlation. AJR Am J Roentgenology 2002; 178:935-938.
15. Dugdale PE, Miles KA, Bunce I, Kelley BB, Leggatt DA. CT measurement of perfusion and permeability within lymphoma masses and its ability to assess grade, activity, and chemotherapeutic response. J Comput Assist Tomogr 1999; 23:540-547.
16. Boiselle PM, Patz EJ, Vining DJ, Weissler R, Sheard JO, McLoud TC. Imaging of mediastinal lymph nodes. CT, MR and FDG-PET. Radiographics 1998; 18:1061-1069.
17. Glazer HS, Lee JKT, Levitt RG, et al. Radiation fibrosis: differentiation from recurrent tumor by MR imaging. Radiology 1985; 156:721-726.
18. Hill M, Cunningham D, MacVicar D, et al. Role of magnetic resonance imaging in predicting relapse in residual masses after treatment of lymphoma. J Clin Oncol 1993; 11:2773-2778.
19. Nyman RS, Rehn SM, Glimelius BL, Hagberg HE, Hemmingsson AL, Sundstrom CJ. Residual mediastinal masses in Hodgkin disease: prediction of size with MR imaging. Radiology 1989; 170:435-440.
20. Altehoefer C, Blum U, Bathmann J, Wustenberg C, Uhrmeister P, Laubenberger J. Comparative diagnostic accuracy of magnetic resonance imaging and immunoscintigraphy for detection of bone marrow involvement in patients with malignant lymphoma. J Clin Oncol 1997; 15:1754-1760.
21. Radford JA, Cowan RA, Flanagan M, et al. The significance of residual mediastinal abnormality on the chest radiograph following treatment for Hodgkin's disease. J Clin Oncol 1988; 6:940-946.
22. Rahmouni A, Tempany C, Jones R, Mann R, Yang A, Zerhouni E. Lymphoma. Monitoring tumor size and signal intensity with MR imaging. Radiology 1993; 188:445-451.
23. Jochelson M, Mauch P, Balikian J, Rosenthal D, Canellos G. The significance of the residual mediastinal mass in treated Hodgkin disease. J Clin Oncol 1985; 3:637-640.
24. Fuks JZ, Aisner J, Wiernik PH. Restaging laparotomy in the management of the non-Hodgkin lymphomas. Med Pediatr. Oncol 1982; 10:429-438.
25. Wernecke K, Vassallo P, Rutsch F, Peters P, Potter R. Thymic involvement in Hodgkin disease: CT and sonographic findings. Radiology 1991; 181:375-383.
26. Stewart FM, Williamson BR, Innes DJ, Hess CE. Residual tumor masses following treatment for advanced histiocytic lymphoma - diagnostic and therapeutic implications. Cancer 1985; 55:620-623.
27. North LB, Fuller LM, Sullivan Halley JA, et al. Regression of mediastinal Hodgkin disease after therapy: evaluation of time interval. Radiology 1987; 164:599-602.
28. Rodriguez-Catarino M, Jerkeman M, Ahlstrom H, Glimelius B, Hagberg H. Residual mass in aggressive lymphoma - does size, measured by computed tomography, influence clinical outcome? Acta Oncol 2000; 39:485-489.
29. Brisse H, Pacquement H, Burdairon E, Plancher C, Neuenschwander S. Outcome of residual mediastinal masses of thoracic lymphomas in children: impact on management and radiological follow-up strategy. PediatrRadiol 1988; 28:444-450.
30. Lee CKK, Bloomfield CD, Goldman AI, Levitt SH. Prognostic significance of mediastinal involvement in Hodgkin disease treated with curative radiotherapy. Cancer 1980; 46:2403-2409.
31. 18SF-FDG PET: age dependency and frequency after chemotherapy. J Nucl Med 2001; 42:591-595.
32. Luber GD, Siegel MJ. Mediastinal Hodgkin disease in children: response to therapy. Radiology 1993; 189:737-740.
33. Parker BR. Leukaemia and lymphoma in childhood. Radiol Clin North Am 1997; 35:1495-1516.
34. Kissin CM, Husband JE, Nicholas D, Eversman W. Benign thymic enlargement in adults after chemotherapy. CT demonstration. Radiology 1987; 163:67-70.
35. Heron CW, Husband JE, Williams MP. Hodgkin disease: CT of the thymus. Radiology 1998; 209:471-475.
36. Spiers ASD, Husband JES, MacVicar AD. Treated thymic lymphoma: comparison of MR imaging with CT. Radiology 1997; 203:369-376.
37. Maisey NR, Hill ME, Webb A, et al. Are 18 fluorodeoxyglucose positron emission tomography and magnetic resonance imaging useful in the prediction of relapse in lymphoma residual masses? Eur J Cancer 2000; 36:200-206.
38. Gossot D, Girard P, de Kerviler E, et al. Thoracoscopy or CT-guided biopsy for residual intrathoracic masses after treatment of lymphoma. Chest 2001; 120:289-294.
39. Coiffer B, Gisselbrecht C, Herbrecht R, et al. LNH-84 regimen. A multicentre study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. J Clin Oncol 1989; 7:1018-1026.
40. Karmazyn B, Ash S, Goshen Y, Yaniv I, Horev G, Kornreich L. Significance of residual abdominal masses in children with abdominal Burkitt's lymphoma. Pediatr Radiol 2001; 31:801-805.
41. Pappa VI, Hussain HK, Reznek RH, et al. Role of image guided core needle biopsy in the management of patients with lymphoma. J Clin Oncol 1996; 14:2427-2430.
42. Rahmouni A, Divine M, Lepage E, et al. Mediastinal lymphoma: quantitative changes in gadolinium enhancement at MR imaging after treatment. Radiology 2001; 219:621-628.
43. Jerusalem G, Beguin Y, Fassotte MF, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for post treatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 1999; 94:429-433.
44. Rodriquez M. Computed tomography, magnetic resonance imaging and positron emission tomography in non-Hodgkin's lymphoma. Acta Radiol 1998; 39 (Suppl):417.
45. Rehn S, Nyman R, Glimelins Bhagberg HE, et al. Non-Hodgkin lymphoma: predicting prognostic grade with MR imaging. Radiology 1990; 176:249-253.
46. Weeks JC, Yeap BY, Canellos G, Shipp MA. Value of follow-up procedures in patients with large-cell lymphoma who achieve a complete remission. J Clin Oncol 1991; 9:1196-1203.
47. Front D, Ben-Haim S, Israel O, et al. Lymphoma: predictive value of Ga-67 scintigraphy after treatment. Radiology 1992; 182:359-363.
48. Romer W, Hanauske AR, Ziegler S, et al. Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. Blood 1998; 91:4464-4471.
49. Chang PJ, Parker BR, Donaldson SS, Thompson EI. Dynamic probabilistic model for determination of optimal timing for surveillance chest radiography in pediatric Hodgkin disease. Radiology 1989; 173:71-75.